BR0111438A - Análogos de ácido barbitúrico como agentes terapeuticos - Google Patents
Análogos de ácido barbitúrico como agentes terapeuticosInfo
- Publication number
- BR0111438A BR0111438A BR0111438-7A BR0111438A BR0111438A BR 0111438 A BR0111438 A BR 0111438A BR 0111438 A BR0111438 A BR 0111438A BR 0111438 A BR0111438 A BR 0111438A
- Authority
- BR
- Brazil
- Prior art keywords
- barbituric acid
- therapeutic agents
- acid analogues
- inhibit
- hif
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"ANáLOGOS DE áCIDO BARBITúRICO COMO AGENTES TERAPEUTICOS". A presente invenção se refere a análogos de ácido barbitúricos os quais inibem a atividade de HIF-1 (por exemplo, a interação entre o HIFl<244> e p300) e, dessa forma, inibem a angiogênese, tumorigênese e condições proliferativas tal como câncer. A presente invenção também se refere a composições farmacêuticas compreendendo tais compostos e ao uso de tais compostos e composições, in vitro e in vivo, para inibir a atividade de HIF-1 e inibir a angiogênese, tumorigênese e condições proliferativas tal como câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0013655.6A GB0013655D0 (en) | 2000-06-05 | 2000-06-05 | Therapeutic compounds |
PCT/GB2001/002468 WO2001093841A2 (en) | 2000-06-05 | 2001-06-05 | Barbituric acid analogs as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0111438A true BR0111438A (pt) | 2003-06-17 |
Family
ID=9893008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0111438-7A BR0111438A (pt) | 2000-06-05 | 2001-06-05 | Análogos de ácido barbitúrico como agentes terapeuticos |
Country Status (14)
Country | Link |
---|---|
US (2) | US20030229108A1 (pt) |
EP (1) | EP1305026B1 (pt) |
JP (1) | JP2003535123A (pt) |
CN (1) | CN1433312A (pt) |
AT (1) | ATE431149T1 (pt) |
AU (1) | AU2001260504A1 (pt) |
BR (1) | BR0111438A (pt) |
CA (1) | CA2410311C (pt) |
DE (1) | DE60138709D1 (pt) |
GB (1) | GB0013655D0 (pt) |
IL (1) | IL153014A0 (pt) |
NZ (1) | NZ522779A (pt) |
WO (1) | WO2001093841A2 (pt) |
ZA (1) | ZA200209439B (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2384428A (en) * | 2002-01-29 | 2003-07-30 | Thromb X Nv | Inhibitors of HIF |
US7288546B1 (en) * | 2003-02-20 | 2007-10-30 | University Of Central Florida | Method and compound for inhibition of cell death |
US20050049267A1 (en) * | 2002-03-01 | 2005-03-03 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
GB0206711D0 (en) | 2002-03-21 | 2002-05-01 | Isis Innovation | HIF Inhibitor |
GB2386892A (en) * | 2002-03-28 | 2003-10-01 | Pantherix Ltd | Carboxy containing (phenyl-/heterocyclyl-)methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
GB2387172A (en) * | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
CA2501144C (en) | 2002-10-23 | 2015-10-06 | University Of Utah Research Foundation | Amplicon melting analysis with saturation dyes |
EP1651226B1 (en) | 2003-07-11 | 2010-02-24 | Proteologics, Inc. | Ubiquitin ligase inhibitors and methods related thereto |
US9657347B2 (en) | 2004-04-20 | 2017-05-23 | University of Utah Research Foundation and BioFire Defense, LLC | Nucleic acid melting analysis with saturation dyes |
US20060194756A1 (en) * | 2004-11-22 | 2006-08-31 | Borea Pier A | Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists |
CA2705694C (en) * | 2007-11-21 | 2015-02-24 | Katholieke Universiteit Leuven, K.U.Leuven R & D | Inhibitors of malt1 proteolytic activity and uses thereof |
KR100965726B1 (ko) * | 2007-11-23 | 2010-06-24 | 재단법인서울대학교산학협력재단 | 피리미딘-2,4,6-트라이온 유도체를 함유하는 Hsp90억제제 및 이를 이용한 항암제 |
CA2723233C (en) * | 2008-05-08 | 2017-06-13 | Nova Southeastern University | Specific inhibitors for vascular endothelial growth factor receptors |
WO2010018458A2 (en) * | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
US8304421B2 (en) * | 2008-09-30 | 2012-11-06 | Vanderbilt University | Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents |
WO2012065139A2 (en) * | 2010-11-11 | 2012-05-18 | Board Of Regents, The University Of Texas System | Entpd5 inhibitors |
US9878998B2 (en) * | 2011-08-18 | 2018-01-30 | Nuhope Llc | Barbiturate and thiobarbiturate compounds for use in cancer therapy |
JP5731718B2 (ja) | 2011-11-11 | 2015-06-10 | ファイザー・インク | 2−チオピリミジノン |
US9873674B2 (en) * | 2012-09-21 | 2018-01-23 | Cornell University | C-Rel inhibitors and uses thereof |
EP2938342A4 (en) | 2012-12-28 | 2016-06-15 | Univ Arkansas | INDOL COMPOUNDS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASE AND CANCER |
JP2016516814A (ja) | 2013-04-19 | 2016-06-09 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | コンブレタスタチン類似体 |
US20160075689A1 (en) * | 2013-04-23 | 2016-03-17 | The Board Of Trustees Of The University Of Arkansas | Polymerase, endonuclease, and helicase inhibitors and methods of using thereof |
US9974788B2 (en) | 2013-09-26 | 2018-05-22 | Beth Israel Deaconess Medical Center, Inc. | Inhibition of SGK1 in the treatment of heart conditions |
US9145374B2 (en) * | 2013-11-20 | 2015-09-29 | National Tsing Hua University | Shikimate pathway inhibitors and the use thereof |
JPWO2015147204A1 (ja) * | 2014-03-27 | 2017-04-13 | 国立大学法人京都大学 | 血管新生増殖因子を阻害する医薬組成物 |
EP3125886A4 (en) | 2014-03-31 | 2017-09-06 | Bioventures, Llc | Disubstituted triazole analogs |
WO2015195951A1 (en) * | 2014-06-18 | 2015-12-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Combination therapy to enhance the anticancer efficacy of platinum drugs |
ES2854707T3 (es) | 2015-02-04 | 2021-09-22 | Beyondbio Inc | Compuesto heterocíclico y composición farmacéutica que comprende el mismo |
MA42035A (fr) | 2015-05-05 | 2018-03-14 | Pfizer | 2-thiopyrimidinones |
KR102260995B1 (ko) * | 2018-11-28 | 2021-06-04 | 국립암센터 | Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3331687A (en) * | 1962-09-24 | 1967-07-18 | Render Belipa G M B H Fa | Electrophotographic material |
DE2042663A1 (de) * | 1970-08-28 | 1972-03-02 | Agfa-Gevaert Ag, 5090 Leverkusen | Photographisches Trockenkopierverfahren |
PL77134B1 (pt) * | 1971-12-29 | 1975-02-28 | ||
US3819595A (en) * | 1972-09-05 | 1974-06-25 | Dow Chemical Co | Nucleation of normally crystalline vinylidene chloride polymers |
SU1129202A1 (ru) * | 1981-09-08 | 1984-12-15 | Предприятие П/Я Г-4740 | Способ получени 2-арилиденкарбонильных соединений |
JPS6229570A (ja) * | 1985-07-29 | 1987-02-07 | Kanegafuchi Chem Ind Co Ltd | 3,5−ジイソプロピルベンジリデン複素環式化合物 |
JPH0196628A (ja) * | 1987-10-08 | 1989-04-14 | Idemitsu Kosan Co Ltd | 有機非線型光学材料 |
US5141943A (en) * | 1990-04-12 | 1992-08-25 | Brown University Research Foundation | 5-benzyl barbiturate derivatives |
WO1994015605A1 (en) * | 1993-01-14 | 1994-07-21 | Cell Therapeutics, Inc. | Acetal or ketal substituted therapeutic compounds |
JPH1048824A (ja) * | 1996-07-31 | 1998-02-20 | Toyobo Co Ltd | 光重合性組成物、それを用いた感光性原版およびその露光方法 |
KR20010074949A (ko) * | 1998-09-04 | 2001-08-09 | 비로파마 인코포레이티드 | 바이러스성 감염 및 관련 질환의 치료 방법 또는 예방 방법 |
DE60037813T2 (de) * | 1999-06-04 | 2009-01-15 | Dana-Farber Cancer Institute, Inc., Boston | Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren |
-
2000
- 2000-06-05 GB GBGB0013655.6A patent/GB0013655D0/en not_active Ceased
-
2001
- 2001-06-05 EP EP01934202A patent/EP1305026B1/en not_active Expired - Lifetime
- 2001-06-05 NZ NZ522779A patent/NZ522779A/en unknown
- 2001-06-05 DE DE60138709T patent/DE60138709D1/de not_active Expired - Fee Related
- 2001-06-05 AT AT01934202T patent/ATE431149T1/de not_active IP Right Cessation
- 2001-06-05 US US10/297,203 patent/US20030229108A1/en not_active Abandoned
- 2001-06-05 JP JP2002501414A patent/JP2003535123A/ja active Pending
- 2001-06-05 CA CA002410311A patent/CA2410311C/en not_active Expired - Fee Related
- 2001-06-05 AU AU2001260504A patent/AU2001260504A1/en not_active Abandoned
- 2001-06-05 CN CN01810729A patent/CN1433312A/zh active Pending
- 2001-06-05 IL IL15301401A patent/IL153014A0/xx unknown
- 2001-06-05 WO PCT/GB2001/002468 patent/WO2001093841A2/en active IP Right Grant
- 2001-06-05 BR BR0111438-7A patent/BR0111438A/pt not_active Application Discontinuation
-
2002
- 2002-11-20 ZA ZA200209439A patent/ZA200209439B/en unknown
-
2008
- 2008-01-16 US US12/015,208 patent/US20080113993A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ522779A (en) | 2004-08-27 |
EP1305026B1 (en) | 2009-05-13 |
CA2410311A1 (en) | 2001-12-13 |
ZA200209439B (en) | 2003-11-20 |
JP2003535123A (ja) | 2003-11-25 |
DE60138709D1 (de) | 2009-06-25 |
EP1305026A2 (en) | 2003-05-02 |
US20080113993A1 (en) | 2008-05-15 |
CN1433312A (zh) | 2003-07-30 |
CA2410311C (en) | 2009-12-29 |
WO2001093841A2 (en) | 2001-12-13 |
ATE431149T1 (de) | 2009-05-15 |
WO2001093841A3 (en) | 2002-06-06 |
US20030229108A1 (en) | 2003-12-11 |
AU2001260504A1 (en) | 2001-12-17 |
IL153014A0 (en) | 2003-06-24 |
GB0013655D0 (en) | 2000-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0111438A (pt) | Análogos de ácido barbitúrico como agentes terapeuticos | |
BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
DK1162982T3 (da) | Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning | |
SE0100568D0 (sv) | Compounds | |
DK1390378T3 (da) | Farmaceutisk aktive uridin estere | |
PT1119543E (pt) | N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y | |
BG66085B1 (bg) | Фенилаланинови производни | |
ATE235895T1 (de) | Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis | |
SE0001899D0 (sv) | New compounds | |
PT1033981E (pt) | Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos | |
ATE554750T1 (de) | Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen | |
BR0012450A (pt) | Benzimidazóis substituìdos | |
BR0115965A (pt) | Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos | |
CO5590918A2 (es) | Formulaciones | |
DK1272160T3 (da) | Lipidbaseret lægemiddelleveringssystem til topisk applikation | |
DE50012571D1 (de) | Biotin enthaltende galenische formulierung | |
PT1140031E (pt) | Preparacao farmaceutica de libertacao controlada com mesilato de tilidina como substancia activa | |
SE0100566D0 (sv) | Compounds | |
BR0010983A (pt) | Preparações para a aplicação de agentes antiinflamatórios | |
GT200000035AA (es) | Derivados de resorcinol, (solicitud fraccionaria no. 1 derivada de la patente pi-2000-0035) | |
ATE253359T1 (de) | Antithrombotische mittel | |
DE59914183D1 (de) | Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz | |
IT1307786B1 (it) | Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali. | |
SE0101692D0 (sv) | Compounds | |
BR0015781A (pt) | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO. |
|
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |